ELSEVIER

Toxicology 102 (1995) 317

TOXICOLOGY

Author index

Volume 102 (1995)

Aguet, M. **102**, 301
Albores, A. **102**, 285
Andersen, M.E. **102**, 221
Anderson, M.W. **102**, 73

Baker, K. **102**, 161
Birnbaum, L.S. **102**, 115
Bucio, L. **102**, 285
Buckley, L.A. **102**, 125

Cárabez, A. **102**, 285
Cebrián, M.E. **102**, 275
Chávez, E. **102**, 285
Clewell III, H.J. **102**, 83
Cohen, S.M. **102**, 149
Conolly, R.B. **102**, 179
Crow, R. **102**, 161

De Vito, M.J. **102**, 115
Devereux, T.R. **102**, 73
Dragan, Y.P. **102**, 161

Elstein, K.H. **102**, 207

Foley, J.F. **102**, 73

García-Vargas, G. **102**, 275
Goddard, M.J. **102**, 53
Graham, J.D. **102**, 29
Greenlee, W.F. **102**, 221
Gutiérrez-Ruiz, M.C. **102**, 285

Hegi, M. **102**, 73
Hernández, A. **102**, 275
Huang, S. **102**, 301
Hully, J. **102**, 161

Jackson, R.C. **102**, 197
Jirtle, R.L. **102**, 221
Jusko, W.J. **102**, 189

Kanno, J. **102**, 73
Kavlock, R.J. **102**, 207
Kohn, M.C. **102**, 133
Krewski, D. **102**, 53

Lau, C. **102**, 207
López, M.L. **102**, 275
Luebeck, E.G. **102**, 141

Maronpot, R.R. **102**, 73
Mass, M.J. **102**, 161
McClellan, R.O. **102**, 239
Mendoza-Figueroa, T. **102**, 275
Mills, J.J. **102**, 221
Moolgavkar, S.H. **102**, 141

Narotsky, M.G. **102**, 207

Oglesby, L.A. **102**, 259
Omenn, G.S. **102**, 23
Ozolins, T.R.S. **102**, 259

Padilla, S. **102**, 215
Pitot, H.C. **102**, 161

Quintanilla-Vega, B. **102**, 275

Reiter, L.W. **102**, 3
Rhomberg, L. **102**, 95
Rogers, J.M. **102**, 207
Ryffel, B. **102**, 301

Saulnier, M. **102**, 301
Sexton, K. **102**, 3
Shuey, D.L. **102**, 207
Sierra, A. **102**, 285
Souza, V. **102**, 285

Wells, P.G. **102**, 259
Wiley, M.J. **102**, 259
Wiseman, R. **102**, 73
Woodrow Setzer, R. **102**, 207

Zenick, H. **102**, 3
Zucker, R.M. **102**, 207

0300-483X/95/$09.50 © 1995 Elsevier Science Ireland Ltd. All rights reserved

ELSEVIER

Toxicology 102 (1995) 318–321

TOXICOLOGY

Subject index

Volume 102 (1995)

α_{2u}-globulin; Risk assessment; Default options; Formaldehyde; Cancer; Extrapolation **102**, 239

2-Acetylaminofluorene; Bladder cancer; Cell proliferation; Calculi; Saccharin; Risk assessment **102**, 149

Acetylcholinesterase; Cholinesterase; Organophosphate pesticides; Carbamate pesticides; Cholinesterase inhibitors; Cholinesterase inhibition, brain; Cholinesterase inhibition, blood; Cholinesterase inhibition, correlation; Cholinesterase inhibitors, risk assessment **102**, 215

Ah receptor; Dioxins; Risk assessment **102**, 115

Allometric scaling; Pharmacokinetics; Dosimetry; Crss-species extrapolation; Mechanistic models **102**, 95

Altered hepatic foci; Initiation; Promotion; Cell proliferation; Apoptosis **102**, 141

Antifolates, teratogenicity; Dihydrofolate reductase; Kinetic modelling; Simulation; Thymidylate synthase **102**, 197

Apoptosis; Initiation; Promotion; Cell proliferation; Altered hepatic foci **102**, 141

BBDR; Default assumptions; Uncertainty; PBPK; Risk assesment; Science policy **102**, 3

Bioactivating system; Cyclophosphamide; Murine embryohepatocyte co-culture model; Embryopathy; Embryotoxicity; Proteratogens **102**, 259

Biological plausibility; Clinical significance; Susceptibility; Value of information model; Tennant-Ashby challenge; Interspecies differences **102**, 23

Biologically-based dose-response; 5-fluorouracil; 5-FU; Mechanisms; Mechanistic modelling; Developmental toxicity **102**, 207

Biologically-based dose-response model; Inhalation exposure; Risk assessment **102**, 73

Bladder cancer; Cell proliferation; Calculi; Saccharin; 2-Acetylaminofluorene; Risk assessment **102**, 149

Cadmium toxicity; Mercury toxicity; Human fetal cell line; Cytotoxicity; WRL-68 cells; Metallothionein **102**, 285

Calculi; Bladder cancer; Cell proliferation; Saccharin; 2-Acetylaminofluorene; Risk assessment **102**, 149

Cancer; Risk assessment; Default options; Formaldehyde; α_{2u}-globulin; Extrapolation **102**, 239

Cancer; Risk assessment; Mechanism; Chloroform; Formaldehyde; Non-cancer **102**, 179

Carbamate pesticides; Acetylcholinesterase; Cholinesterase; Organophosphate pesticides; Cholinesterase inhibitors; Cholinesterase inhibition, brain; Cholinesterase inhibition, blood; Cholinesterase inhibition, correlation; Cholinesterase inhibitors, risk assessment **102**, 215

Carcinogén; Risk assessment; Safety **102**, 29

Cell proliferation; Bladder cancer; Calculi; Saccharin; 2-Acetylaminofluorene; Risk assessment **102**, 149

Cell proliferation; Initiation; Promotion; Apoptosis; Altered hepatic foci **102**, 141

Chloroform; Risk assessment; Mechanism; Formaldehyde; Cancer; Non-cancer **102**, 179

Cholinesterase; Acetylcholinesterase; Organophosphate pesticides; Carbamate pesticides; Cholinesterase inhibitors; Cholinesterase inhibition, brain; Cholinesterase inhibition, blood; Cholinesterase inhibition, correlation; Cholinesterase inhibitors, risk assessment **102**, 215

0300-483X/95/$09.50 © 1995 Elsevier Science Ireland Ltd. All rights reserved

Cholinesterase inhibition, blood; Acetylcholinesterase; Cholinesterase; Organophosphate pesticides; Carbamate pesticides; Cholinesterase inhibitors; Cholinesterase inhibition, brain; Cholinesterase inhibition, correlation; Cholinesterase inhibitors, risk assessment **102**, 215

Cholinesterase inhibition, brain; Acetylcholinesterase; Cholinesterase; Organophosphate pesticides; Carbamate pesticides; Cholinesterase inhibitors; Cholinesterase inhibition, blood; Cholinesterase inhibition, correlation; Cholinesterase inhibitors, risk assessment **102**, 215

Cholinesterase inhibition, correlation; Acetylcholinesterase; Cholinesterase; Organophosphate pesticides; Carbamate pesticides; Cholinesterase inhibitors; Cholinesterase inhibition, brain; Cholinesterase inhibition, blood; Cholinesterase inhibitors, risk assessment **102**, 215

Cholinesterase inhibitors; Acetylcholinesterase; Cholinesterase; Organophosphate pesticides; Carbamate pesticides; Cholinesterase inhibition, brain; Cholinesterase inhibition, blood; Cholinesterase inhibition, correlation; Cholinesterase inhibitors, risk assessment **102**, 215

Cholinesterase inhibitors, risk assessment; Acetylcholinesterase; Cholinesterase; Organophosphate pesticides; Carbamate pesticides; Cholinesterase inhibitors; Cholinesterase inhibition, brain; Cholinesterase inhibition, blood; Cholinesterase inhibition, correlation **102**, 215

Clinical significance; Biological plausibility; Susceptibility; Value of information model; Tennant-Ashby challenge; Interspecies differences **102**, 23

Contact hypersensitivity; IFNγ; IFNγ-R knockout mouse; Oxazolone; TNCB **102**, 301

Cross-species extrapolation; Pharmacokinetics; Dosimetry; Mechanistic models; Allometric scaling **102**, 95

Cyclophosphamide; Murine embryo-hepatocyte co-culture model; Embryopathy; Embryotoxicity; Proteratogens; Bioactivating system **102**, 259

Cytotoxicity; Cadmium toxicity; Mercury toxicity; Human fetal cell line; WRL-68 cells; Metallothionein **102**, 285

Default assumptions; BBDR; Uncertainty; PBPK; Risk assesment; Science policy **102**, 3

Default options; Risk assessment; Formaldehyde; Cancer; α_{2u}-globulin; Extrapolation **102**, 239

Developmental toxicity; 5-fluorouracil; 5-FU; Mechanisms; Mechanistic modelling; Biologically-based dose-response **102**, 207

Dihydrofolate reductase; Antifolates, teratogenicity; Kinetic modelling; Simulation; Thymidylate synthase **102**, 197

Dioxin; Pharmacokinetics; Models **102**, 125

Dioxins; Ah receptor; Risk assessment **102**, 115

Dosimetry; Hepatocarcogenesis; Receptor **102**, 133

Dosimetry; Pharmacokinetics; Cross-species extrapolation; Mechanistic models; Allometric scaling **102**, 95

Embryopathy; Cyclophosphamide; Murine embryo-hepatocyte co-culture model; Embryotoxicity; Proteratogens; Bioactivating system **102**, 259

Embryotoxicity; Cyclophosphamide; Murine embryo-hepatocyte co-culture model; Embryopathy; Proteratogens; Bioactivating system **102**, 259

Extrapolation; Risk assessment; Default options; Formaldehyde; Cancer; α_{2u}-globulin **102**, 239

5-fluorouracil; 5-FU; Mechanisms; Mechanistic modelling; Developmental toxicity; Biologically-based dose-response **102**, 207

Formaldehyde; Risk assessment; Default options; Cancer; α_{2u}-globulin; Extrapolation **102**, 239

Formaldehyde; Risk assessment; Mechanism; Chloroform; Cancer; Non-cancer **102**, 179

5-FU; 5-fluorouracil; Mechanisms; Mechanistic modelling; Developmental toxicity; Biologically-based dose-response **102**, 207

Hepatocarcogenesis; Dosimetry; Receptor **102**, 133

Human fetal cell line; Cadmium toxicity; Mercury toxicity; Cytotoxicity; WRL-68 cells; Metallothionein **102**, 285

IFNγ; IFNγ-R knockout mouse; Contact hypersensitivity; Oxazolone; TNCB **102**, 301

IFNγ-R knockout mouse; IFNγ; Contact hypersensitivity; Oxazolone; TNCB **102**, 301

Inhalation exposure; Biologically-based dose-response model; Risk assessment **102**, 73

Initiation; Promotion; Cell proliferation; Apoptosis; Altered hepatic foci **102**, 141

Interspecies differences; Biological plausibility; Clinical significance; Susceptibility; Value of information model; Tennant-Ashby challenge **102**, 23

Kinetic modelling; Antifolates, teratogenicity; Dihydrofolate reductase; Simulation; Thymidylate synthase **102**, 197

Lead exposure; Porphyrin production; Rat hepatocyte; Long-term culture **102**, 275
Long-term culture; Porphyrin production; Rat hepatocyte; Lead exposure **102**, 275

Mathematical models; Methylprednisolone; Prednisolone **102**, 189

Mathematical models; PGST; Placental glutathione *S*-transferase **102**, 161

Mathematical models; TCDD; 2,3,7,8,-Tetrachlorodibenzo-*p*-dioxin; Transforming growth factor beta 1; TGF-β **102**, 221

Mechanism; Risk assessment; Chloroform; Formaldehyde; Cancer; Non-cancer **102**, 179

Mechanisms; 5-fluorouracil; 5-FU; Mechanistic modelling; Developmental toxicity; Biologically-based dose-response **102**, 207

Mechanistic modelling; 5-fluorouracil; 5-FU; Mechanisms; Developmental toxicity; Biologically-based dose-response **102**, 207

Mechanistic models; Pharmacokinetics; Dosimetry; Cross-species extrapolation; Allometric scaling **102**, 95

Mercury toxicity; Cadmium toxicity; Human fetal cell line; Cytotoxicity; WRL-68 cells; Metallothionein **102**, 285

Metallothionein; Cadmium toxicity; Mercury toxicity; Human fetal cell line; Cytotoxicity; WRL-68 cells **102**, 285

Methylene chloride; Risk assessment; Pharmacokinetic modeling **102**, 83

Methylprednisolone; Mathematical models; Prednisolone **102**, 189

Models; Dioxin; Pharmacokinetics **102**, 125

Murine embryo-hepatocyte co-culture model; Cyclophosphamide; Embryopathy; Embryotoxicity; Proteratogens; Bioactivating system **102**, 259

Non-cancer; Risk assessment; Mechanism; Chloroform; Formaldehyde; Cancer **102**, 179

Organophosphate pesticides; Acetylcholinesterase; Cholinesterase; Carbamate pesticides; Cholinesterase inhibitors; Cholinesterase inhibition, brain; Cholinesterase inhibition, blood; Cholinesterase inhibition, correlation; Cholinesterase inhibitors, risk assessment **102**, 215

Oxazolone; IFNγ; IFNγ-R knockout mouse; Contact hypersensitivity; TNCB **102**, 301

PBPK; BBDR; Default assumptions; Uncertainty; Risk assesment; Science policy **102**, 3

PGST; Mathematical models; Placental glutathione *S*-transferase **102**, 161

Pharmacokinetic modeling; Risk assessment; Methylene chloride **102**, 83

Pharmacokinetics; Dioxin; Models **102**, 125

Pharmacokinetics; Dosimetry; Cross-species extrapolation; Mechanistic models; Allometric scaling **102**, 95

Placental glutathione *S*-transferase; Mathematical models; PGST **102**, 161

Porphyrin production; Rat hepatocyte; Long-term culture; Lead exposure **102**, 275

Prednisolone; Mathematical models; Methylprednisolone **102**, 189

Promotion; Initiation; Cell proliferation; Apoptosis; Altered hepatic foci **102**, 141

Proteratogens; Cyclophosphamide; Murine embryo-hepatocyte co-culture model; Embryopathy; Embryotoxicity; Bioactivating system **102**, 259

Rat hepatocyte; Porphyrin production; Long-term culture; Lead exposure **102**, 275

Receptor; Dosimetry; Hepatocarcogenesis **102**, 133

Risk assesment; BBDR; Default assumptions; Uncertainty; PBPK; Science policy **102**, 3

Risk assessment; Biologically-based dose-response model; Inhalation exposure **102**, 73

Risk assessment; Bladder cancer; Cell proliferation; Calculi; Saccharin; 2-Acetylaminofluorene **102**, 149

Risk assessment; Carcinogen; Safety **102**, 29

Risk assessment; Default options; Formaldehyde; Cancer; α_{2u}-globulin; Extrapolation **102**, 239

Risk assessment; Dioxins; Ah receptor **102**, 115

Risk assessment; Mechanism; Chloroform; Formaldehyde; Cancer; Non-cancer **102**, 179

Risk assessment; Methylene chloride; Pharmacokinetic modeling **102**, 83

Saccharin; Bladder cancer; Cell proliferation; Calculi; 2-Acetylaminofluorene; Risk assessment **102**, 149

Safety; Risk assessment; Carcinogen **102**, 29

Science policy; BBDR; Default assumptions; Uncertainty; PBPK; Risk assesment **102**, 3

Simulation; Antifolates, teratogenicity; Dihydrofolate reductase; Kinetic modelling; Thymidylate synthase **102**, 197

Susceptibility; Biological plausibility; Clinical significance; Value of information model; Tennant-Ashby challenge; Interspecies differences **102**, 23

TCDD; Mathematical models; 2,3,7,8,-Tetrachlorodibenzo-*p*-dioxin; Transforming growth factor beta 1; TGF-*β* **102**, 221

Tennant-Ashby challenge; Biological plausibility; Clinical significance; Susceptibility; Value of information model; Interspecies differences **102**, 23

2,3,7,8,-Tetrachlorodibenzo-*p*-dioxin; Mathematical models; TCDD; Transforming growth factor beta 1; TGF-*β* **102**, 221

TGF-*β*; Mathematical models; TCDD; 2,3,7,8,-tetrachlorodibenzo-*p*-dioxin; Transforming growth factor beta 1 **102**, 221

Thymidylate synthase; Antifolates, teratogenicity; Dihydrofolate reductase; Kinetic modelling; Simulation **102**, 197

TNCB; IFNγ; IFNγ-R knockout mouse; Contact hypersensitivity; Oxazolone **102**, 301

Transforming growth factor beta 1; Mathematical models; TCDD; 2,3,7,8,-Tetrachlorodibenzo-*p*-dioxin; TGF-*β* **102**, 221

Uncertainty; BBDR; Default assumptions; PBPK; Risk assesment; Science policy **102**, 3

Value of information model; Biological plausibility; Clinical significance; Susceptibility; Tennant-Ashby challenge; Interspecies differences **102**, 23

WRL-68 cells; Cadmium toxicity; Mercury toxicity; Human fetal cell line; Cytotoxicity; Metallothionein **102**, 285